Scholar Rock Holding Corporation $SRRK Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. grew its stake in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) by 5.7% during the fourth quarter, Holdings Channel reports. The firm owned 5,195,465 shares of the company’s stock after purchasing an additional 280,538 shares during the period. Vanguard Group Inc. owned approximately 0.05% of Scholar Rock worth $228,860,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Three Seasons Wealth LLC boosted its holdings in shares of Scholar Rock by 2.1% in the 4th quarter. Three Seasons Wealth LLC now owns 10,968 shares of the company’s stock valued at $483,000 after buying an additional 222 shares in the last quarter. Principal Financial Group Inc. raised its stake in Scholar Rock by 7.9% during the 3rd quarter. Principal Financial Group Inc. now owns 6,214 shares of the company’s stock worth $231,000 after acquiring an additional 456 shares in the last quarter. California State Teachers Retirement System lifted its position in Scholar Rock by 0.9% in the second quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock valued at $2,209,000 after acquiring an additional 577 shares during the last quarter. Tema Etfs LLC lifted its position in Scholar Rock by 6.6% in the fourth quarter. Tema Etfs LLC now owns 9,899 shares of the company’s stock valued at $436,000 after acquiring an additional 616 shares during the last quarter. Finally, E Fund Management Co. Ltd. boosted its stake in Scholar Rock by 6.8% in the second quarter. E Fund Management Co. Ltd. now owns 11,146 shares of the company’s stock valued at $395,000 after acquiring an additional 710 shares in the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Wall Street Analyst Weigh In

SRRK has been the subject of several research reports. Piper Sandler boosted their target price on Scholar Rock from $51.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday, March 4th. Barclays raised their price target on Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday. Canaccord Genuity Group started coverage on Scholar Rock in a research report on Monday, April 20th. They set a “buy” rating and a $62.00 price target on the stock. Citigroup increased their price objective on Scholar Rock from $55.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Finally, JPMorgan Chase & Co. raised their target price on shares of Scholar Rock from $47.00 to $50.00 and gave the stock an “overweight” rating in a research report on Monday, March 16th. Five research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $56.00.

Scholar Rock Trading Up 4.2%

Shares of Scholar Rock stock opened at $48.39 on Friday. The firm has a market cap of $5.77 billion, a price-to-earnings ratio of -13.48 and a beta of 0.70. Scholar Rock Holding Corporation has a 52-week low of $27.07 and a 52-week high of $51.63. The company’s 50-day simple moving average is $46.15 and its 200-day simple moving average is $43.00. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.41.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same quarter in the previous year, the business posted ($0.67) EPS. As a group, equities research analysts anticipate that Scholar Rock Holding Corporation will post -3.11 earnings per share for the current year.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, CFO Vikas Sinha sold 10,410 shares of the company’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $49.57, for a total transaction of $516,023.70. Following the transaction, the chief financial officer directly owned 619,856 shares in the company, valued at approximately $30,726,261.92. This represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Keith Woods sold 10,220 shares of the stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $49.57, for a total transaction of $506,605.40. Following the completion of the transaction, the chief operating officer directly owned 620,055 shares of the company’s stock, valued at approximately $30,736,126.35. This trade represents a 1.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 102,736 shares of company stock worth $4,977,900. 13.30% of the stock is currently owned by company insiders.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).